Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

The Tobias and Lechleiter families donated $20 million to establish the Institute for Clinical Innovation at IU Health, the ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly and Company has agreed to acquire SiteOne Therapeutics Inc., a private biotech company developing small molecule ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

The Therapeutic Goods Administration has approved a new drug tipped to revolutionise the treatment of hundreds of thousands of Australians suffering through early-stage Alzheimer’s disease.

The Tobias-Lechleiter Institute for Clinical Innovation will serve as a hub for "groundbreaking" disease detection and ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Eli Lilly and Company (NYSE:LLY) is advancing its neuroscience portfolio by acquiring SiteOne Therapeutics in a deal valued ...